Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.
Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications.
Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.
Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
October 2023—Eiger Diagnostics has been formed to provide high-quality parasitology and infectious disease diagnostics worldwide. Eiger’s first product releases are parasitology serology IgG and IgM ELISA assays. The company plans to add to its product portfolio this year.
October 2023—PixCell Medical announced that the FDA has granted 510(k) clearance for direct capillary sampling with the HemoScreen 5-part differential CBC analyzer. The clearance enables collection of a sample directly from a patient’s finger without an intermediate tube. HemoScreen is also FDA cleared for point-of-care use with venous and capillary blood.
October 2023—Pillar Biosciences announced the global launch of OncoReveal Core LBx, a research use only, liquid biopsy–based next-generation sequencing kit for pan-cancer tumor profiling. The panel interrogates 104 clinically relevant genes in one multiplex reaction, analyzes cfDNA present in plasma for genetic alterations in cancer, including assessment of microsatellite instability, and can batch more than 20 clinical samples on a single Illumina NextSeq run. Mutation detection performance is as low as 0.1 percent.
October 2023—Wren Laboratories launched its PRRT (peptide receptor radionuclide therapy) Predictor Quotient, or PPQ, a companion diagnostic to its NETest, a liquid-biopsy neuroendocrine tumor diagnostic. The test classifies patients as either a responder, a patient who will experience disease stabilization and have a longer time to disease progression (usually greater than 18 months after the end of PRRT treatment), or as a nonresponder, who will have a shorter time until the disease progresses (usually less than 12 months after the start of PRRT). According to a research paper published in April (Bodei L, et al. J Nucl Med. 2023;64[9]:1329–1330), the PPQ delivers 96 percent accuracy in determining patient response to PRRT.
October 2023—Abbott has received FDA clearance for its Alinity h-series hematology system, which includes the Alinity hq, an automated hematology analyzer, and Alinity hs, an integrated slide maker and stainer. The Alinity hq leverages multiangle polarized scatter separation (MAPPS) technology, which uses light scattering to distinguish cellular features and identify various blood cells, and processes up to 119 CBC results per hour. The system can be integrated into an existing core lab operation.
October 2023—Sophia Genetics announced the expansion of its relationship with Gustave Roussy in which the cancer center will use the Sophia DDM digital analytics platform for all relevant samples, including those related to solid tumors and hematologic and hereditary cancers. Gustave Roussy, which has two campuses in France, began working with the cloud-native software company in 2017. Sophia Genetics is located in France and Boston.
October 2023—Verichem Laboratories offers multilevel enzyme calibration verification materials for liver function testing as part of its liquid-stable Enzyme ER Verifier kit. The kit contains the enzymes alanine aminotransferase (ALT/SGPT), alkaline phosphatase (AP/ALP), aspartate aminotransferase (AST/SGOT), gamma-glutamyl transferase (GGT/GGTP), lactate dehydrogenase (LD/LDH), amylase, cholinesterase, creatine phosphokinase, and lipase. Its proprietary formulation is designed to include at least one concentration for each enzyme within the normal range. The verifiers are intended to be treated as patient specimens and are compatible with wet chemistry systems from Abbott, Beckman Coulter, Roche, and Siemens Healthineers. Shelf life is 18 months.
October 2023—Primera Technology has launched its next-generation Signature EVO slide printer and Signature EVO cassette printer.
October 2023—Visiopharm and Boston Cell Standards announced they are partnering to integrate immunohistochemistry calibration standards with image analysis software for quality assurance. The joint technology solution will enable laboratories to meet key provisions of regulatory changes proposed in an editorial published in Archives of Pathology & Laboratory Medicine.
September 2023—Illumina and Pillar Biosciences announced a strategic partnership to make Pillar’s suite of oncology assays commercially available worldwide as part of Illumina’s portfolio of oncology products. The companies say the agreement will result in an unprecedented offering of complementary next-generation sequencing solutions that will enhance the efficiency, accuracy, and cost-effectiveness of oncology testing through advanced sequencing techniques.
